Radiology Department, St Johns' Cancer Center, Lublin, Poland.
Public Independent Clinical Hospital Number 4, Lublin, Poland.
Folia Med Cracov. 2022;62(2):93-107. doi: 10.24425/fmc.2022.141702.
Tenosynovial Giant Cell Tumor (TGCT) is a group of typically benign lesions arising from the synovium of joints, bursae and tendon sheaths. Depending on their growth pattern and clinical course, they are divided into localized and diffuse types. It is predominantly caused by a mutation in the stromal cells of the synovial membrane leading to overexpression of the colony stimulating factor 1 that recruits CSF1R-expressing cells of the mononuclear phagocyte lineage into the tumor mass. The lesions contain mainly histiocyte-like and synovial cells accompanied by varying numbers of multinucleated giant cells, mononuclear cells, foam cells, inflammatory cells and hemosiderin deposits. The gold standard for detect- ing and monitoring the disease is MRI, where the characteristic hemosiderin accumulation can be best appreciated, but it is a histological examination that is most conclusive. The main treatment is surgical resection of all pathological tissue, but radio- and chemotherapy are also viable options for certain groups of patients.
腱鞘巨细胞瘤(TGCT)是一组源自关节、滑囊和腱鞘滑膜的典型良性病变。根据其生长模式和临床病程,可分为局限性和弥漫性。它主要是由滑膜基质细胞中的突变引起,导致集落刺激因子 1 的过度表达,募集单核吞噬细胞谱系中表达 CSF1R 的细胞进入肿瘤组织。病变主要包含组织细胞样细胞和滑膜细胞,伴有不同数量的多核巨细胞、单核细胞、泡沫细胞、炎性细胞和含铁血黄素沉积。检测和监测疾病的金标准是 MRI,在 MRI 中可以最好地观察到特征性的含铁血黄素堆积,但最具结论性的是组织学检查。主要治疗方法是切除所有病理组织,但放射和化学疗法也是某些患者群体的可行选择。